Five Prime Therapeutics IncFPRX
A clinical-stage biopharmaceutical company developing novel cancer immunotherapies, primarily focused on targeting the CSF1R pathway to modulate tumor-associated macrophages. Its lead candidate, cabiralizumab, was being evaluated in combination with nivolumab for solid tumors, though development was discontinued after a strategic review. Investors tracked the company for its early immuno-oncology pipeline and its acquisition by Bristol Myers Squibb in 2021.
Congressional Interest in Five Prime Therapeutics Inc (FPRX)
1 member of Congress has disclosed 1 trade in Five Prime Therapeutics Inc (FPRX), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Who in Congress Is Trading FPRX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2019-01-22 | MICHAEL T. MCCAUL | buy | $1K-$15K |